Lisa Miller Sells 47,912 Shares of LifeStance Health Group (NASDAQ:LFST) Stock

LifeStance Health Group, Inc. (NASDAQ:LFSTGet Free Report) COO Lisa Miller sold 47,912 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $10.85, for a total value of $519,845.20. Following the transaction, the chief operating officer owned 281,289 shares of the company’s stock, valued at approximately $3,051,985.65. This trade represents a 14.55% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

LifeStance Health Group Stock Up 6.3%

LifeStance Health Group stock traded up $0.73 during midday trading on Wednesday, reaching $12.23. The stock had a trading volume of 6,069,213 shares, compared to its average volume of 3,433,701. The stock has a market capitalization of $4.74 billion, a P/E ratio of 94.08 and a beta of 1.14. LifeStance Health Group, Inc. has a 1-year low of $4.77 and a 1-year high of $12.43. The firm’s fifty day simple moving average is $10.10 and its 200-day simple moving average is $8.12. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.38 and a current ratio of 1.38.

LifeStance Health Group (NASDAQ:LFSTGet Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. LifeStance Health Group had a net margin of 3.19% and a return on equity of 3.39%. The company had revenue of $435.35 million for the quarter, compared to the consensus estimate of $414.58 million. During the same period last year, the company earned ($0.01) earnings per share. The firm’s revenue was up 26.1% compared to the same quarter last year. As a group, analysts expect that LifeStance Health Group, Inc. will post 0.14 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on LFST. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of LifeStance Health Group in a report on Wednesday, May 27th. KeyCorp lifted their target price on LifeStance Health Group from $11.00 to $13.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. Zacks Research downgraded LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Barclays raised their target price on shares of LifeStance Health Group from $9.00 to $13.00 and gave the company an “overweight” rating in a report on Tuesday, July 14th. Finally, Canaccord Genuity Group upped their price objective on LifeStance Health Group from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $11.62.

Check Out Our Latest Stock Analysis on LFST

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Royal Bank of Canada increased its position in shares of LifeStance Health Group by 63.4% during the first quarter. Royal Bank of Canada now owns 70,248 shares of the company’s stock worth $468,000 after buying an additional 27,244 shares during the period. AQR Capital Management LLC raised its position in shares of LifeStance Health Group by 223.0% in the 1st quarter. AQR Capital Management LLC now owns 51,500 shares of the company’s stock worth $343,000 after acquiring an additional 35,554 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of LifeStance Health Group by 3.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 142,950 shares of the company’s stock worth $952,000 after acquiring an additional 4,169 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of LifeStance Health Group by 1.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 615,652 shares of the company’s stock valued at $4,100,000 after purchasing an additional 11,331 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in shares of LifeStance Health Group by 10.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 550,657 shares of the company’s stock valued at $2,847,000 after purchasing an additional 51,154 shares in the last quarter. Institutional investors own 85.50% of the company’s stock.

About LifeStance Health Group

(Get Free Report)

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.

Featured Stories

Insider Buying and Selling by Quarter for LifeStance Health Group (NASDAQ:LFST)

Receive News & Ratings for LifeStance Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeStance Health Group and related companies with MarketBeat.com's FREE daily email newsletter.